Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Offering complete therapeutic solutions to patients, Sanofi has a long history in the development of medicines, such as oral anti-diabetics and insulins, medical devices and services for the treatment of metabolic disorders, diabetes and cardiovascular complications.

Sanofi has a long experience in leading and participating in IMI projects, in particular in the field of Diabetes and Metabolic Disorders, such as IMI 2 INNODIA, RHAPSODY, BEAt-DKD and LITMUS or IMI 1 IMIDIA, SUMMIT and DIRECT.

Dr. Robert Wright, PharmD

Robert is Senior Director for Strategic Planning and Transversal Scientific Projects in Diabetes and Cardiovascular Global Medical Affairs at Sanofi. With more than 20 years of experience in academia and the pharmaceutical industry, he has led US and global medical affairs teams for a number of high profile cardiovascular and diabetes products at multiple companies, including Glucophage, Glucovance, Plavix, Eliquis, Onglyza, Epanova, and Crestor. He will serve as the industry co-lead for WP3.

Marcus Korn, PhD

Marcus is an experienced biochemist with a focus on insulin biology, insulin design and gene expression analysis studies.

Matt Reaney

Matt Reaney is a Chartered Practitioner Health Psychologist, a Chartered Scientist and a Fellow of the Royal Societies of Medicine, Public Health and British Psychological Society (Associate). Matt is the Global Head of Clinical Outcomes at Sanofi and retains academic links as Guest Lecturer at Royal Holloway University of London. Matt is a member of the Psychosocial Aspects of Diabetes (PSAD) study group of the EASD and Behavioural Research in Diabetes Group Exchange (BRIDGE), and is the chair of the DIA Study Endpoints Community (SEC).

Chantal Le Floch, PharmD

Chantal is a pharmacist with more than 25 years’ experience in pharmaceutical industry. Involved in several development plan & EU registration activities (Scientific Advices, Pediatric Investigation Plans, Marketing Authorization Application …) of Diabetes drugs including definition of hypoglycaemic episodes using the European Agency definition.

Krister Blokvist, PharmD, PhD

Krister is the Cluster Head for Islet Biology and has more than 20 years’ experience in the pharma industry working in the fields of incretins and islet biology. Krister has worked on two marketed diabetes drugs and has moved several drug candidates into clinical development. His scientific background is focused on the stimulus secretion-coupling in pancreatic alpha and beta-cells.

Niels Porksen, MD

Niels is Global Project Head Early Development.

Marek Demissie, MD

Marek is Senior Clinical Research Director.

Stéfanie Fayolle

Stéfanie is Senior Manager Clinical Data Trial Sharing.

Marc D. Voss, PhD, MBA

Marc is coordinating public private partnerships within Sanofi Strategy and Business Development, with more than 16 years’ experience in the pharmaceutical industry working in different roles as Scientist, Senior Scientist, Contract Manager, Head of Laboratory and Project Team Leader for different Diabetes drug discovery projects within R&D.